<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02723201</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-020-1002</org_study_id>
    <secondary_id>U1111-1171-4650</secondary_id>
    <secondary_id>2015-002635-18</secondary_id>
    <secondary_id>16/WA/0012</secondary_id>
    <nct_id>NCT02723201</nct_id>
  </id_info>
  <brief_title>TAK-020 Relative Bioavailability and Food Effect Study in Healthy Participants</brief_title>
  <official_title>A Randomized, Open Label Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of a Single Dose of Various Test Solid Formulations of TAK-020 Compared With a Single Dose of Reference Oral Solution and to Evaluate the Food Effect and Potentially the Dose Proportionality of the Optimal Solid Dose Formulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the relative bioavailability of solid oral
      formulations of TAK-020 in comparison with single dose of TAK-020 oral solution formulation
      and to evaluate the food effect and potentially the dose proportionality of the optimal oral
      solid formulation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TAK-020 is being developed for the potential treatment of autoimmune diseases including
      rheumatoid arthritis. Currently TAK-020 is available as an oral solution. This study is to
      develop an oral tablet formulation. There are three parts to this study. Part 1 will compare
      different tablet formulations of TAK-020 compared to a reference oral solution to identify
      the best tablet formulation to use in Parts 2 and 3. Part 2 will look at the effect food has
      on TAK-020. Part 3 is optional; its implementation will be decided upon using data from Part
      2. It will evaluate whether increased doses of TAK-020 produce an expected proportional
      increase in the plasma concentration of TAK-020.

      In Part 1 participants will receive a single dose of the following:

      Period 1: TAK-020 Oral Solution Period 2: TAK-020 Co-Crystal Tablet Period 3: TAK-020 Solid
      Dispersion Tablet Period 4: TAK-020 Immediate Release Tablet

      In Part 2 participants will be split into two groups; one will receive the chosen formulation
      of TAK-020 in the fasted state followed by the fed state and the other group will receive it
      in the fed state followed by the fasted state. The dose used in Part 2 will be based upon
      data from Part 1 and previous studies.

      Participants in Part 3 of the study will be split into 2 cohorts. Each cohort will be
      administered, in the fasted state, a single dose of the tablet selected as optimal from
      previous study parts. The dose used will be based upon data from Parts 1 and 2 and previous
      studies.

      Part 1 will assess the relative bioavailability of TAK-020 by using analysis of variance
      (ANOVA) on tmax, and the natural logarithms of AUCs, and Cmax. Part 2 will assess the food
      effect of TAK-020, also using ANOVA on tmax, and the natural logarithms of AUCs, and Cmax.
      The power model will be used to assess dose proportionality of single doses of the solid
      formulations in the fasted state from Parts 2 and 3.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 28, 2016</start_date>
  <completion_date type="Actual">August 24, 2016</completion_date>
  <primary_completion_date type="Actual">August 5, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for TAK-020</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-020</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-020</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Disposition Phase Half-life (T1/2z) in Plasma for TAK-020</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experience at Least One or More Treatment-emergent Adverse Event (TEAE)</measure>
    <time_frame>Baseline up to 30 days after last dose of study drug (Day 58 in Part 1), (Day 40 in Part 2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Meet the Takeda Markedly Abnormal Criteria for Clinical Laboratory Tests at Least Once Post Dose</measure>
    <time_frame>Baseline up to Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Meet the Takeda Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post Dose</measure>
    <time_frame>Baseline up to Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Meet the Takeda Markedly Abnormal Criteria for Safety 12-lead Electrocardiogram (ECG) Parameters at Least Once Post Dose</measure>
    <time_frame>Baseline up to Day 2</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part-1, Period 1: TAK-020 17.5 mg Oral Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose 17.5 milligram (mg), on Day 1, followed by 7 days of washout. Dose will be determined from TAK-020 single rising dose (SRD) trial.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part-1, Period 2: TAK-020 17.5 mg Co-crystal Tablet (CCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose 17.5 mg, on Day 1, followed by 7 days of washout. Dose will be the same as Part 1, Period 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part-1, Period 3:TAK-020 17.5 mg Solid Dispersion Tablet (SDT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose 17.5 mg, on Day 1, followed by 7 days of washout. Dose will be the same as Part 1, Period 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part-1, Period 4:TAK-020 17.5 mg Immediate Release Tablet(IRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose 17.5 mg, on Day 1, followed by 7 days of washout. Dose will be the same as Part 1, Period 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, Period 1: TAK-020 25 mg CCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to AB or BA crossover where A= Fasted, B =Fed. Sequence I: Single oral dose TAK-020 25 mg, Fasted (A), 7 days washout, single oral dose TAK-020 Fed (B) Sequence II: Single oral dose TAK-020 25 mg, Fed (B), 7 days washout, single oral dose TAK-020 Fasted (A) Dose will be determined from SRD trial and Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part- 3 Cohort 1: TAK-020 Solid Formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose on Day 1. Dose will be determined from SRD trial and Parts 1 and 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3 Cohort 2: TAK-020 Solid Formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose on Day 1. Dose will be determined from SRD trial and Parts 1 and 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-020 Captisol Oral Solution</intervention_name>
    <description>TAK-020 solution.</description>
    <arm_group_label>Part-1, Period 1: TAK-020 17.5 mg Oral Solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-020 CCT</intervention_name>
    <description>TAK-020 co-crystal tablet</description>
    <arm_group_label>Part-1, Period 2: TAK-020 17.5 mg Co-crystal Tablet (CCT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-020 SDT</intervention_name>
    <description>TAK-020 Solid dispersion tablet.</description>
    <arm_group_label>Part-1, Period 3:TAK-020 17.5 mg Solid Dispersion Tablet (SDT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-020 IRT</intervention_name>
    <description>TAK-020 immediate release tablet.</description>
    <arm_group_label>Part-1, Period 4:TAK-020 17.5 mg Immediate Release Tablet(IRT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-020 CCT</intervention_name>
    <description>TAK-020 co-crystal tablet.</description>
    <arm_group_label>Part 2, Period 1: TAK-020 25 mg CCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-020 Solid Formulation</intervention_name>
    <description>TAK-020 solid formulation</description>
    <arm_group_label>Part- 3 Cohort 1: TAK-020 Solid Formulation</arm_group_label>
    <arm_group_label>Part 3 Cohort 2: TAK-020 Solid Formulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Is capable of understanding and complying with protocol requirements.

          2. Is legally acceptable representative signs and dates a written, informed consent form
             and any required privacy authorization prior to the initiation of any study procedures
             including requesting that a participant fast for any laboratory evaluations.

          3. Is a healthy adult male or female.

          4. Is aged 18 to 55 years, inclusive, at the time of informed consent and first study
             medication dose.

          5. Weighs at least 45 kilogram (kg) and has a body mass index (BMI) between 18 and 32
             kilogram per square meter (kg/m^2), inclusive at Screening and Day -1.

          6. Male participant who is nonsterilized and sexually active with a female partner of
             childbearing potential agrees to use adequate contraception from signing of informed
             consent throughout the duration of the study and for 90 days after last dose of study
             medication.

          7. Female participant of childbearing potential who is sexually active with a
             nonsterilized male partner agrees to use routinely adequate contraception from signing
             of informed consent and throughout the duration of the study and until the next
             menstrual period or 90 days after exit from the study, whichever is first. If the next
             menstrual period is delayed, a pregnancy test will be required for exclusion of
             pregnancy.

        Exclusion Criteria:

          1. Has received any investigational compound within 30 days prior to Screening.

          2. Is an immediate family member, study site employee, or is in a dependent relationship
             with a study site employee who is involved in the conduct of this study (example,
             spouse, parent, child, sibling) or may consent under duress.

          3. Has a known hypersensitivity to any component of the formulation of TAK-020, Captisol,
             or related compounds.

          4. Has a positive urine drug result for drugs of abuse or a positive breath alcohol
             screen at Screening or Check-in (Day -1).

          5. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol
             abuse (defined as 4 or more alcoholic units per day) within 1 year prior to the
             Screening visit or is unwilling to agree to abstain from alcohol and drugs throughout
             the study.

          6. Has taken any excluded medication, supplements, or food products listed in Prohibited
             Medications and Foods table.

          7. If female, is pregnant or lactating or intending to become pregnant before, during or
             within 3 months after exit from this study (90 days post last dose); or intending to
             donate ova during such time period.

          8. If male, the participant intends to donate sperm during the course of this study or
             for 90 days after the last dose of study drug.

          9. Has evidence of current cardiovascular, central nervous system, hepatic, hematopoietic
             disease, renal dysfunction, metabolic or endocrine dysfunction, serious allergy,
             asthma hypoxemia, hypertension, seizures, or allergic skin rash.

         10. Has current or recent (within 6 months) gastrointestinal disease that would be
             expected to influence the absorption of drugs (that is, a history of malabsorption,
             esophageal reflux, peptic ulcer disease, erosive esophagitis, frequent [more than once
             per week] occurrence of heartburn, or any surgical intervention [example,
             cholecystectomy]).

         11. Has a history of cancer, except basal cell carcinoma which has been in remission for
             at least 5 years prior to Day 1.

         12. Has used nicotine-containing products (including but not limited to cigarettes, pipes,
             cigars, chewing tobacco, nicotine patch or nicotine gum) within 28 days prior to
             Check-in Day -1. Cotinine test is positive at Screening or Check-in (Day -1).

         13. Has poor peripheral venous access.

         14. Has donated or lost 450 mililiter (mL) or more of his or her blood volume (including
             plasmapheresis), or had a transfusion of any blood product within 30 days prior to Day
             1.

         15. Has a Screening or Check-in (Day -1) abnormal (clinically significant) ECG. Entry of
             any participant with an abnormal (not clinically significant) ECG must be approved,
             and documented by signature by the principal investigator or medically qualified
             subinvestigator.

         16. Has QT interval with Fridericia correction method (QTcF) greater than (&gt;) 430
             millisecond (msec) for men and &gt;450 msec for women or PR outside the range of 120 to
             220 msec confirmed upon repeat testing within a maximum of 30 minutes, at the
             Screening Visit or Check-in (Day -1).

         17. Has abnormal Screening or Day -1 laboratory values that suggest a clinically
             significant underlying disease or participant with the following lab abnormalities:

               1. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) &gt;1.2* the
                  upper limit of normal (ULN).

               2. Positive screen test for drugs of abuse.

               3. Positive blood screen for hepatitis B surface antigen (HBsAg), hepatitis C virus
                  (HCV), or human immunodeficiency virus-1 or -2 antibodies (test done at Screening
                  visit only).

               4. A positive test for tuberculosis (TB) (QuantiFERON) (test done at Screening Visit
                  only).

         18. Vaccination with any live vaccine within 4 weeks of study drug administration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2016</study_first_submitted>
  <study_first_submitted_qc>March 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2016</study_first_posted>
  <results_first_submitted>August 17, 2017</results_first_submitted>
  <results_first_submitted_qc>April 9, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 13, 2018</results_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 1 investigative site in the United Kingdom from 28 April 2016 to 24 August 2016.</recruitment_details>
      <pre_assignment_details>Healthy participants were enrolled in 3 part study to receive TAK-020. Part-1: relative bio-availability of solid formulations, Part-2: effect of food on co-crystal tablet(CCT) and Part-3: dose linearity of CCT. Part-3 was not conducted, as relative bioavailability of solid formulation was greater than(&gt;) 50% compared with oral solution of TAK-020.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part 1- TAK-020 17.5 mg: OS + CCT + SDT + IRT</title>
          <description>TAK-020 17.5 milligram (mg), oral solution (OS), under fasted state, once on Day 1 of first intervention period; followed by 7 days washout period, followed by TAK-020 17.5 mg, CCT, orally, under fasted state, once on Day 1 of second intervention period; followed by 7 days washout period, followed by TAK-020 17.5 mg, solid dispersion tablets (SDT), orally, under fasted state, once on Day 1 of third intervention period; followed by 7 days washout period, followed by TAK-020 17.5 mg, immediate release tablets (IRT), orally, under fasted state, once on Day 1 of fourth intervention period.</description>
        </group>
        <group group_id="P2">
          <title>Part 2- TAK-020 25 mg CCT: Fasted + Fed</title>
          <description>TAK-020 25 mg, CCT, orally, under fasted state, once on Day 1 of first intervention period, followed by 7 days of washout period, further followed by TAK-020 25 mg, CCT, orally, under fed, once on Day 1 of second intervention period.</description>
        </group>
        <group group_id="P3">
          <title>Part 2- TAK-020 25 mg CCT: Fed + Fasted</title>
          <description>TAK-020 25 mg, CCT, orally, under fed state, once on Day 1 of first intervention period, followed by 7 days of washout period, further followed by TAK-020 25 mg, CCT, orally, under fasted state, once on Day 1 of second intervention period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Third Intervention Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Fourth Intervention Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The safety analysis set included all participants who were enrolled and received 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Part 1: TAK-020 17.5 mg</title>
          <description>TAK-020 17.5 mg, OS, under fasted state, once on Day 1 of first intervention period; followed by 7 days washout period, followed by TAK-020 17.5 mg, CCT, orally, under fasted state, once on Day 1 of second intervention period; followed by 7 days washout period, followed by TAK-020 17.5 mg, SDT, orally, under fasted state, once on Day 1 of third intervention period; followed by 7 days washout period, followed by TAK-020 17.5 mg, IRT, orally, under fasted state, once on Day 1 of fourth intervention period.</description>
        </group>
        <group group_id="B2">
          <title>Part 2- TAK-020 25 mg CCT: Fasted + Fed</title>
          <description>TAK-020 25 mg, CCT, orally, under fasted state, once on Day 1 of first intervention period, followed by 7 days of washout period, further followed by TAK-020 25 mg, CCT, orally, under fed, once on Day 1 of second intervention period.</description>
        </group>
        <group group_id="B3">
          <title>Part 2- TAK-020 25 mg CCT: Fed + Fasted</title>
          <description>TAK-020 25 mg, CCT, orally, under fed state, once on Day 1 of first intervention period, followed by 7 days of washout period, further followed by TAK-020 25 mg, CCT, orally, under fasted state, once on Day 1 of second intervention period.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.7" spread="8.82"/>
                    <measurement group_id="B2" value="31.1" spread="6.49"/>
                    <measurement group_id="B3" value="38.9" spread="12.36"/>
                    <measurement group_id="B4" value="39.3" spread="10.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeter (cm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171.7" spread="10.40"/>
                    <measurement group_id="B2" value="172.3" spread="7.36"/>
                    <measurement group_id="B3" value="173.0" spread="6.51"/>
                    <measurement group_id="B4" value="172.2" spread="8.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilogram (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.16" spread="16.448"/>
                    <measurement group_id="B2" value="74.26" spread="11.454"/>
                    <measurement group_id="B3" value="75.50" spread="10.207"/>
                    <measurement group_id="B4" value="76.32" spread="13.212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kilogram per square meter (kg/m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.23" spread="3.140"/>
                    <measurement group_id="B2" value="24.91" spread="2.724"/>
                    <measurement group_id="B3" value="25.19" spread="2.884"/>
                    <measurement group_id="B4" value="25.57" spread="2.900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Classification</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Never smoked</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Current smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Ex-smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol Classification</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Never drinks</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Current drinker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Ex-drinker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Caffeine/Xanthine Classification</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Caffeine/xanthine consumption</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No caffeine/xanthine consumption</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Female Reproductive Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="7"/>
                    <count group_id="B4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Surgically sterile</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Female of childbearing potential</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not applicable (male participants)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Amount of Alcohol Consumed by Participant</title>
          <population>Baseline measure was analyzed only for those participants who were current drinker and had alcohol consumption.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Less than (&lt;) 4 drinks per day</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 or more drinks per day</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax: Maximum Observed Plasma Concentration for TAK-020</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose</time_frame>
        <population>The pharmacokinetic (PK) set where Day 1 assessment were available. The PK set included all participants who received study drug and had at least 1 measurable plasma concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: TAK-020 17.5 mg OS</title>
            <description>TAK-020 17.5 mg, OS, once under fasted state on Day 1 of first intervention period. A washout period of 7 day was maintained between each intervention period.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: TAK-020 17.5 mg CCT</title>
            <description>TAK-020 17.5 mg, CCT, orally under fasted state, once on Day 1 of second intervention period. A washout period of 7 day was maintained between each intervention period.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: TAK-020 17.5 mg SDT</title>
            <description>TAK-020 17.5 mg, SDT, orally under fasted state, once on Day 1 of third intervention period. A washout period of 7 day was maintained between each intervention period.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: TAK-020 17.5 mg IRT</title>
            <description>TAK-020 17.5 mg, IRT, orally under fasted state, once on Day 1 of fourth intervention period.</description>
          </group>
          <group group_id="O5">
            <title>Part 2: TAK-020 25 mg CCT Fasted</title>
            <description>TAK-020 25 mg, CCT, orally under fasted state, once on Day 1 of either first intervention period or second intervention period.</description>
          </group>
          <group group_id="O6">
            <title>Part 2: TAK-020 25 mg CCT Fed</title>
            <description>TAK-020 25 mg, CCT, orally under fed state, once on Day 1 of either first intervention period or second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Observed Plasma Concentration for TAK-020</title>
          <population>The pharmacokinetic (PK) set where Day 1 assessment were available. The PK set included all participants who received study drug and had at least 1 measurable plasma concentration.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.182" spread="35.0658"/>
                    <measurement group_id="O2" value="44.800" spread="26.4189"/>
                    <measurement group_id="O3" value="139.522" spread="71.6739"/>
                    <measurement group_id="O4" value="6.012" spread="1.8606"/>
                    <measurement group_id="O5" value="63.314" spread="34.1699"/>
                    <measurement group_id="O6" value="40.629" spread="17.6750"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of variance (ANOVA) was performed on the natural logarithms of Cmax with regimen as the fixed effects and participant as the random effect. The point estimate and 90 percent (%) confidence interval (CI) was obtained by taking the antilog of the difference in the log transformed least square (LS) means and its CI, respectively.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.402</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.320</ci_lower_limit>
            <ci_upper_limit>0.505</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>ANOVA was performed on the natural logarithms of Cmax with regimen as the fixed effects and participant as the random effect. The point estimate and 90% CI was obtained by taking the antilog of the difference in the log transformed LS means and its CI, respectively.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.249</p_value>
            <method>ANOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.216</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.016</ci_lower_limit>
            <ci_upper_limit>1.455</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>ANOVA was performed on the natural logarithms of Cmax with regimen as the fixed effects and participant as the random effect. The point estimate and 90% CI was obtained by taking the antilog of the difference in the log transformed LS means and its CI, respectively.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.055</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.041</ci_lower_limit>
            <ci_upper_limit>0.074</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>ANOVA was performed on the natural logarithms of Cmax with regimen as the fixed effects and participant as the random effect. The point estimate and 90% CI was obtained by taking the antilog of the difference in the log transformed LS means and its CI, respectively.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.054</p_value>
            <method>ANOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.685</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.499</ci_lower_limit>
            <ci_upper_limit>0.939</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-020</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose</time_frame>
        <population>The PK set where Day 1 assessment were available. The PK set included all participants who received study drug and had at least 1 measurable plasma concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: TAK-020 17.5 mg OS</title>
            <description>TAK-020 17.5 mg, OS, once under fasted state on Day 1 of first intervention period. A washout period of 7 day was maintained between each intervention period.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: TAK-020 17.5 mg CCT</title>
            <description>TAK-020 17.5 mg, CCT, orally under fasted state, once on Day 1 of second intervention period. A washout period of 7 day was maintained between each intervention period.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: TAK-020 17.5 mg SDT</title>
            <description>TAK-020 17.5 mg, SDT, orally under fasted state, once on Day 1 of third intervention period. A washout period of 7 day was maintained between each intervention period.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: TAK-020 17.5 mg IRT</title>
            <description>TAK-020 17.5 mg, IRT, orally under fasted state, once on Day 1 of fourth intervention period.</description>
          </group>
          <group group_id="O5">
            <title>Part 2: TAK-020 25 mg CCT Fasted</title>
            <description>TAK-020 25 mg, CCT, orally under fasted state, once on Day 1 of either first intervention period or second intervention period.</description>
          </group>
          <group group_id="O6">
            <title>Part 2: TAK-020 25 mg CCT Fed</title>
            <description>TAK-020 25 mg, CCT, orally under fed state, once on Day 1 of either first intervention period or second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-020</title>
          <population>The PK set where Day 1 assessment were available. The PK set included all participants who received study drug and had at least 1 measurable plasma concentration.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.530" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O2" value="1.000" lower_limit="0.50" upper_limit="2.00"/>
                    <measurement group_id="O3" value="0.750" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O4" value="1.000" lower_limit="0.75" upper_limit="6.00"/>
                    <measurement group_id="O5" value="1.000" lower_limit="0.50" upper_limit="2.00"/>
                    <measurement group_id="O6" value="2.000" lower_limit="0.75" upper_limit="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-020</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose</time_frame>
        <population>The PK set where Day 1 assessment were available. The PK set included all participants who received study drug and had at least 1 measurable plasma concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: TAK-020 17.5 mg OS</title>
            <description>TAK-020 17.5 mg, OS, once under fasted state on Day 1 of first intervention period. A washout period of 7 day was maintained between each intervention period.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: TAK-020 17.5 mg CCT</title>
            <description>TAK-020 17.5 mg, CCT, orally under fasted state, once on Day 1 of second intervention period. A washout period of 7 day was maintained between each intervention period.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: TAK-020 17.5 mg SDT</title>
            <description>TAK-020 17.5 mg, SDT, orally under fasted state, once on Day 1 of third intervention period. A washout period of 7 day was maintained between each intervention period.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: TAK-020 17.5 mg IRT</title>
            <description>TAK-020 17.5 mg, IRT, orally under fasted state, once on Day 1 of fourth intervention period.</description>
          </group>
          <group group_id="O5">
            <title>Part 2: TAK-020 25 mg CCT Fasted</title>
            <description>TAK-020 25 mg, CCT, orally under fasted state, once on Day 1 of either first intervention period or second intervention period.</description>
          </group>
          <group group_id="O6">
            <title>Part 2: TAK-020 25 mg CCT Fed</title>
            <description>TAK-020 25 mg, CCT, orally under fed state, once on Day 1 of either first intervention period or second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-020</title>
          <population>The PK set where Day 1 assessment were available. The PK set included all participants who received study drug and had at least 1 measurable plasma concentration.</population>
          <units>nanogram*hour per milliliter (ng*hr/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="257.455" spread="97.5416"/>
                    <measurement group_id="O2" value="164.485" spread="72.4927"/>
                    <measurement group_id="O3" value="316.448" spread="127.4409"/>
                    <measurement group_id="O4" value="32.783" spread="18.5993"/>
                    <measurement group_id="O5" value="220.396" spread="89.7255"/>
                    <measurement group_id="O6" value="185.935" spread="29.6651"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ANOVA was performed on the natural logarithms of AUC∞ with regimen as the fixed effects and participant as the random effect. The point estimate and 90% CI was obtained by taking the antilog of the difference in the log transformed LS means and its CI, respectively.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>ANOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.648</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.497</ci_lower_limit>
            <ci_upper_limit>0.844</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>ANOVA was performed on the natural logarithms of AUC∞ with regimen as the fixed effects and participant as the random effect. The point estimate and 90% CI was obtained by taking the antilog of the difference in the log transformed LS means and its CI, respectively.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.423</p_value>
            <method>ANOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.180</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.088</ci_lower_limit>
            <ci_upper_limit>1.279</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>ANOVA was performed on the natural logarithms of AUC∞ with regimen as the fixed effects and participant as the random effect. The point estimate and 90% CI was obtained by taking the antilog of the difference in the log transformed LS means and its CI, respectively.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.116</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.077</ci_lower_limit>
            <ci_upper_limit>0.176</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>ANOVA was performed on the natural logarithms of AUC∞ with regimen as the fixed effects and participant as the random effect. The point estimate and 90% CI was obtained by taking the antilog of the difference in the log transformed LS means and its CI, respectively.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.037</p_value>
            <method>ANOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.836</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.731</ci_lower_limit>
            <ci_upper_limit>0.957</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Disposition Phase Half-life (T1/2z) in Plasma for TAK-020</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose</time_frame>
        <population>The PK set where Day 1 assessment were available. The PK set included all participants who received study drug and had at least 1 measurable plasma concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: TAK-020 17.5 mg OS</title>
            <description>TAK-020 17.5 mg, OS, once under fasted state on Day 1 of first intervention period. A washout period of 7 day was maintained between each intervention period.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: TAK-020 17.5 mg CCT</title>
            <description>TAK-020 17.5 mg, CCT, orally under fasted state, once on Day 1 of second intervention period. A washout period of 7 day was maintained between each intervention period.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: TAK-020 17.5 mg SDT</title>
            <description>TAK-020 17.5 mg, SDT, orally under fasted state, once on Day 1 of third intervention period. A washout period of 7 day was maintained between each intervention period.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: TAK-020 17.5 mg IRT</title>
            <description>TAK-020 17.5 mg, IRT, orally under fasted state, once on Day 1 of fourth intervention period.</description>
          </group>
          <group group_id="O5">
            <title>Part 2: TAK-020 25 mg CCT Fasted</title>
            <description>TAK-020 25 mg, CCT, orally under fasted state, once on Day 1 of either first intervention period or second intervention period.</description>
          </group>
          <group group_id="O6">
            <title>Part 2: TAK-020 25 mg CCT Fed</title>
            <description>TAK-020 25 mg, CCT, orally under fed state, once on Day 1 of either first intervention period or second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Disposition Phase Half-life (T1/2z) in Plasma for TAK-020</title>
          <population>The PK set where Day 1 assessment were available. The PK set included all participants who received study drug and had at least 1 measurable plasma concentration.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.695" spread="1.0781" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O2" value="4.661" spread="1.4147" lower_limit="0.50" upper_limit="2.00"/>
                    <measurement group_id="O3" value="3.976" spread="0.9787" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O4" value="5.005" spread="2.8545" lower_limit="0.75" upper_limit="6.00"/>
                    <measurement group_id="O5" value="6.183" spread="0.8914" lower_limit="0.50" upper_limit="2.00"/>
                    <measurement group_id="O6" value="4.412" spread="1.2323" lower_limit="0.75" upper_limit="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experience at Least One or More Treatment-emergent Adverse Event (TEAE)</title>
        <time_frame>Baseline up to 30 days after last dose of study drug (Day 58 in Part 1), (Day 40 in Part 2)</time_frame>
        <population>The safety analysis set included all participants who were enrolled and received 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: TAK-020 17.5 mg OS</title>
            <description>TAK-020 17.5 mg, OS, once under fasted state on Day 1 of first intervention period. A washout period of 7 day was maintained between each intervention period.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: TAK-020 17.5 mg CCT</title>
            <description>TAK-020 17.5 mg, CCT, orally under fasted state, once on Day 1 of second intervention period. A washout period of 7 day was maintained between each intervention period.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: TAK-020 17.5 mg SDT</title>
            <description>TAK-020 17.5 mg, SDT, orally under fasted state, once on Day 1 of third intervention period. A washout period of 7 day was maintained between each intervention period.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: TAK-020 17.5 mg IRT</title>
            <description>TAK-020 17.5 mg, IRT, orally under fasted state, once on Day 1 of fourth intervention period.</description>
          </group>
          <group group_id="O5">
            <title>Part 2: TAK-020 25 mg CCT Fasted</title>
            <description>TAK-020 25 mg, CCT, orally under fasted state, once on Day 1 of either first intervention period or second intervention period.</description>
          </group>
          <group group_id="O6">
            <title>Part 2: TAK-020 25 mg CCT Fed</title>
            <description>TAK-020 25 mg, CCT, orally under fed state, once on Day 1 of either first intervention period or second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experience at Least One or More Treatment-emergent Adverse Event (TEAE)</title>
          <population>The safety analysis set included all participants who were enrolled and received 1 dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Meet the Takeda Markedly Abnormal Criteria for Clinical Laboratory Tests at Least Once Post Dose</title>
        <time_frame>Baseline up to Day 2</time_frame>
        <population>The safety analysis set included all participants who were enrolled and received 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: TAK-020 17.5 mg OS</title>
            <description>TAK-020 17.5 mg, OS, once under fasted state on Day 1 of first intervention period. A washout period of 7 day was maintained between each intervention period.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: TAK-020 17.5 mg CCT</title>
            <description>TAK-020 17.5 mg, CCT, orally under fasted state, once on Day 1 of second intervention period. A washout period of 7 day was maintained between each intervention period.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: TAK-020 17.5 mg SDT</title>
            <description>TAK-020 17.5 mg, SDT, orally under fasted state, once on Day 1 of third intervention period. A washout period of 7 day was maintained between each intervention period.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: TAK-020 17.5 mg IRT</title>
            <description>TAK-020 17.5 mg, IRT, orally under fasted state, once on Day 1 of fourth intervention period.</description>
          </group>
          <group group_id="O5">
            <title>Part 2: TAK-020 25 mg CCT Fasted</title>
            <description>TAK-020 25 mg, CCT, orally under fasted state, once on Day 1 of either first intervention period or second intervention period.</description>
          </group>
          <group group_id="O6">
            <title>Part 2: TAK-020 25 mg CCT Fed</title>
            <description>TAK-020 25 mg, CCT, orally under fed state, once on Day 1 of either first intervention period or second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Meet the Takeda Markedly Abnormal Criteria for Clinical Laboratory Tests at Least Once Post Dose</title>
          <population>The safety analysis set included all participants who were enrolled and received 1 dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematology</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chemistry</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Meet the Takeda Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post Dose</title>
        <time_frame>Baseline up to Day 2</time_frame>
        <population>The safety analysis set included all participants who were enrolled and received 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: TAK-020 17.5 mg OS</title>
            <description>TAK-020 17.5 mg, OS, once under fasted state on Day 1 of first intervention period. A washout period of 7 day was maintained between each intervention period.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: TAK-020 17.5 mg CCT</title>
            <description>TAK-020 17.5 mg, CCT, orally under fasted state, once on Day 1 of second intervention period. A washout period of 7 day was maintained between each intervention period.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: TAK-020 17.5 mg SDT</title>
            <description>TAK-020 17.5 mg, SDT, orally under fasted state, once on Day 1 of third intervention period. A washout period of 7 day was maintained between each intervention period.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: TAK-020 17.5 mg IRT</title>
            <description>TAK-020 17.5 mg, IRT, orally under fasted state, once on Day 1 of fourth intervention period.</description>
          </group>
          <group group_id="O5">
            <title>Part 2: TAK-020 25 mg CCT Fasted</title>
            <description>TAK-020 25 mg, CCT, orally under fasted state, once on Day 1 of either first intervention period or second intervention period.</description>
          </group>
          <group group_id="O6">
            <title>Part 2: TAK-020 25 mg CCT Fed</title>
            <description>TAK-020 25 mg, CCT, orally under fed state, once on Day 1 of either first intervention period or second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Meet the Takeda Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post Dose</title>
          <population>The safety analysis set included all participants who were enrolled and received 1 dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Meet the Takeda Markedly Abnormal Criteria for Safety 12-lead Electrocardiogram (ECG) Parameters at Least Once Post Dose</title>
        <time_frame>Baseline up to Day 2</time_frame>
        <population>The safety analysis set included all participants who were enrolled and received 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: TAK-020 17.5 mg OS</title>
            <description>TAK-020 17.5 mg, OS, once under fasted state on Day 1 of first intervention period. A washout period of 7 day was maintained between each intervention period.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: TAK-020 17.5 mg CCT</title>
            <description>TAK-020 17.5 mg, CCT, orally under fasted state, once on Day 1 of second intervention period. A washout period of 7 day was maintained between each intervention period.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: TAK-020 17.5 mg SDT</title>
            <description>TAK-020 17.5 mg, SDT, orally under fasted state, once on Day 1 of third intervention period. A washout period of 7 day was maintained between each intervention period.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: TAK-020 17.5 mg IRT</title>
            <description>TAK-020 17.5 mg, IRT, orally under fasted state, once on Day 1 of fourth intervention period.</description>
          </group>
          <group group_id="O5">
            <title>Part 2: TAK-020 25 mg CCT Fasted</title>
            <description>TAK-020 25 mg, CCT, orally under fasted state, once on Day 1 of either first intervention period or second intervention period.</description>
          </group>
          <group group_id="O6">
            <title>Part 2: TAK-020 25 mg CCT Fed</title>
            <description>TAK-020 25 mg, CCT, orally under fed state, once on Day 1 of either first intervention period or second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Meet the Takeda Markedly Abnormal Criteria for Safety 12-lead Electrocardiogram (ECG) Parameters at Least Once Post Dose</title>
          <population>The safety analysis set included all participants who were enrolled and received 1 dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events are adverse events that started after the first dose of study drug and up to 30 days after last dose of study drug (Day 58 in Part 1), (Day 40 in Part 2)</time_frame>
      <desc>At each visit, investigator had to document any occurrence of adverse events and abnormal laboratory findings.Any event spontaneously reported by participant/observed by investigator was recorded,irrespective of relation to study treatment.Number at risk included those participants who have actually received the mentioned intervention during study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Part 1: TAK-020 17.5 mg OS</title>
          <description>TAK-020 17.5 mg, OS, once under fasted state on Day 1 of first intervention period. A washout period of 7 day was maintained between each intervention period.</description>
        </group>
        <group group_id="E2">
          <title>Part 1: TAK-020 17.5 mg CCT</title>
          <description>TAK-020 17.5 mg, CCT, orally under fasted state, once on Day 1 of second intervention period. A washout period of 7 day was maintained between each intervention period.</description>
        </group>
        <group group_id="E3">
          <title>Part 1: TAK-020 17.5 mg SDT</title>
          <description>TAK-020 17.5 mg, SDT, orally under fasted state, once on Day 1 of third intervention period. A washout period of 7 day was maintained between each intervention period.</description>
        </group>
        <group group_id="E4">
          <title>Part 1: TAK-020 17.5 mg IRT</title>
          <description>TAK-020 17.5 mg, IRT, orally under fasted state, once on Day 1 of fourth intervention period.</description>
        </group>
        <group group_id="E5">
          <title>Part 2: TAK-020 25 mg CCT Fasted</title>
          <description>TAK-020 25 mg, CCT, orally under fasted state, once on Day 1 of either first intervention period or second intervention period.</description>
        </group>
        <group group_id="E6">
          <title>Part 2: TAK-020 25 mg CCT Fed</title>
          <description>TAK-020 25 mg, CCT, orally under fed state, once on Day 1 of either first intervention period or second intervention period.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda’s sole discretion.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Takeda</name_or_title>
      <organization>Medical Director</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

